VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
GYREGyre Therapeutics, Inc.
$6.29$610M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksGYREQuarterly Cash Flow

Gyre Therapeutics, Inc. (GYRE) Quarterly Cash Flow Statement

120+ quarters historyFree accessUpdated daily

Gyre Therapeutics, Inc. (GYRE) quarterly cash flow statement — complete operating, investing & financing history

GYRE Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23
Cash from Operations3.18M-5.63M4.68M2.09M-129K-2.76M1.68M-5.61M2.88M3.36M7.58M4.53M
Operating CF Margin %14.12%-15.12%15.3%7.8%-0.58%-9.9%6.58%-22.25%10.61%12.38%23.66%15.46%
Operating CF Growth %2565.12%-103.95%179%137.21%-104.47%-182.08%-77.9%-223.8%-72.31%327.8%204.19%136.87%
Net Income-8.69M-2.4M5.94M1.58M3.73M569K1.12M3.53M9.94M-100.98M7.51M3.77M
Depreciation & Amortization672K656K649K641K535K471K454K238K415K308K202K318K
Stock-Based Compensation04.6M1.15M906K507K567K0011K7.28M00
Deferred Taxes-738K831K-531K-300K-191K-592K0-97K-313K-403K-199K-230K
Other Non-Cash Items2.42M159K-72K-446K-1.37M-152K2.02M-1.9M-4.41M95.68M689K18K
Working Capital Changes9.51M-9.47M-2.45M-289K-3.35M-3.62M-1.93M-7.38M-2.76M1.47M-620K657K
Change in Receivables10.47M-9.67M-1.19M-2.61M1.52M-5.47M-536K-3.28M1K-1.35M-810K-454K
Change in Inventory-1.01M-1.21M72K-954K-1.54M-118K-636K-719K-666K184K921K117K
Change in Payables139K-433K483K-51K14K-190K28K-60K-23K297K-144K-117K
Cash from Investing-3.06M1.85M-1.25M-3.04M1.97M-2M-2.39M-8.27M-7.22M1.34M-5.4M-8.05M
Capital Expenditures-183K-144K-668K-256K-122K65K-696K-1.46M-231K-2.32M-1.97M-2.48M
CapEx % of Revenue0.81%0.39%2.19%0.96%0.55%0.23%2.73%5.77%0.85%8.56%6.16%8.45%
Acquisitions6K00000-5K218K05.02M00
Investments------------
Other Investing0-30K-15K-5K-698K-672K07.04M50K42K-639K133K
Cash from Financing21K318K365K22.35M1.34M964K374K275K658K2.5M00
Debt Issued (Net)000000000000
Equity Issued (Net)21K318K023M509K0374K275K0000
Dividends Paid000000000000
Share Repurchases000000000000
Other Financing00365K-649K835K964K00658K2.5M00
Net Change in Cash431K-3.33M3.91M21.45M3.23M-4.05M-231K-13.69M-3.72M7.43M2.35M-4.42M
Free Cash Flow3M-5.77M3.99M1.81M-950K-3.5M983K-7.07M2.65M1.03M5.61M2.06M
FCF Margin %13.33%-15.51%13.06%6.76%-4.31%-12.57%3.86%-28.02%9.76%3.81%17.5%7.01%
FCF Growth %416%-64.69%306.21%125.59%-135.81%-438.45%-82.47%-443.94%-69.42%-5.99%177.04%113.82%
FCF per Share0.03-0.060.040.02-0.01-0.030.01-0.070.030.010.070.03
FCF Conversion (FCF/Net Income)-0.37x3.26x1.30x4.72x-0.05x27.86x1.49x-1.59x0.38x-0.03x1.91x2.45x
Interest Paid000000000000
Taxes Paid00687K447K3.36M761K001.44M01.38M3.54M